1. Search Result
Search Result
Results for "

onset

" in MCE Product Catalog:

24

Inhibitors & Agonists

2

Screening Libraries

1

Peptides

3

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-B0546
    Procaine

    Histone Demethylase DNA/RNA Synthesis Neurological Disease Cancer
    Procaine is a DNA-demethylating agent. Procaine acts through multiple targets and has a slow onset and a short duration of action.
  • HY-B0546A
    Procaine hydrochloride

    Histone Demethylase DNA/RNA Synthesis Neurological Disease Cancer
    Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.
  • HY-105077A
    Nemifitide diTFA

    INN 00835 diTFA

    5-HT Receptor Neurological Disease
    Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF). Nemifitide diTFA can cross the blood-brain barrier.
  • HY-145578
    Linaprazan glurate

    Others Inflammation/Immunology
    Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1).
  • HY-113202
    Stearoylcarnitine

    Endogenous Metabolite Metabolic Disease Neurological Disease
    Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia.
  • HY-113202S
    Stearoyl-L-carnitine-d3

    Endogenous Metabolite Metabolic Disease Neurological Disease
    Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia.
  • HY-B0387
    Ibutilide fumarate

    U70226E

    Calcium Channel Cardiovascular Disease
    Ibutilide fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.
  • HY-111817
    ACT-451840

    Parasite Infection
    ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial.
  • HY-B0546AS
    Procaine-d4 hydrochloride

    Histone Demethylase DNA/RNA Synthesis Neurological Disease Cancer
    Procaine-d4 hydrochloride is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.
  • HY-136066
    Tauro-ω-muricholic acid sodium

    TωMCA sodium

    Others Metabolic Disease
    Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies
  • HY-101059
    FGIN 1-27

    Others Neurological Disease
    FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a Ki of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions.
  • HY-10787
    Ximelagatran

    H 376/95

    Thrombin Cardiovascular Disease
    Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
  • HY-Y0378
    D-Leucine

    (R)-Leucine

    Endogenous Metabolite Neurological Disease
    D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro.
  • HY-12956
    Dinoprost

    Prostaglandin F2α; PGF2α

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
  • HY-108519
    AS1892802

    ROCK Neurological Disease
    AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain.
  • HY-117290
    BMS-962212

    Factor Xa Cardiovascular Disease
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity.
  • HY-12956A
    Dinoprost tromethamine salt

    Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour.
  • HY-10787S
    Ximelagatran-d11

    H 376/95-d11

    Thrombin Cardiovascular Disease
    Ximelagatran-d11 (H 376/95-d11) is the deuterium labeled Ximelagatran. Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
  • HY-A0014
    Ramelteon

    TAK-375

    Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
  • HY-143656
    SH379

    Autophagy Endocrinology
    SH379 is the derivative of 2-methylpyrimidine-fused tricyclic diterpene. SH379 is a potent and orally active anti-late-onset hypogonadism agent. SH379 significantly promotes the expression of the key testosterone synthesis-related enzymes StAR and 3β-HSD. SH379 stimulates autophagy through regulating AMPK/mTOR signaling pathway.
  • HY-12956S
    Dinoprost-d4

    Prostaglandin F2a-d4; PGF2α-d4

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost-d4 (Prostaglandin F2a-d4) is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
  • HY-12956S1
    Dinoprost-d9

    Prostaglandin F2a-d9; PGF2α-d9

    Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Endocrinology
    Dinoprost-d9 (Prostaglandin F2a-d9) is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
  • HY-136528
    RA-9

    Deubiquitinase Apoptosis Cancer
    RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells.
  • HY-108506
    Licarbazepine

    BIA 2-005; GP 47779

    Sodium Channel Neurological Disease
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.